Passage Bio Inc
PASG
Company Profile
Business description
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target critical underlying pathology of neurodegenerative diseases.
Contact
2005 Market Street
39th Floor, One Commerce Square
PhiladelphiaPA19103
USAT: +1 267 866-0311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
60
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,743.60 | 30.00 | -0.34% |
| CAC 40 | 7,659.90 | 102.59 | 1.36% |
| DAX 40 | 23,836.90 | 187.60 | 0.79% |
| Dow JONES (US) | 43,386.84 | 404.41 | 0.94% |
| FTSE 100 | 8,770.16 | 34.56 | 0.40% |
| HKSE | 24,257.39 | 68.01 | -0.28% |
| NASDAQ | 20,167.91 | 194.36 | 0.97% |
| Nikkei 225 | 40,150.79 | 566.21 | 1.43% |
| NZX 50 Index | 12,583.59 | 103.54 | 0.83% |
| S&P 500 | 6,141.02 | 48.86 | 0.80% |
| S&P/ASX 200 | 8,514.20 | 36.60 | -0.43% |
| SSE Composite Index | 3,424.23 | 24.23 | -0.70% |